Your browser is no longer supported. Please, upgrade your browser.
Settings
CLVS Clovis Oncology, Inc. daily Stock Chart
CLVS [NASD]
Clovis Oncology, Inc.
Index- P/E- EPS (ttm)-9.08 Insider Own0.50% Shs Outstand43.49M Perf Week-1.40%
Market Cap3.06B Forward P/E- EPS next Y-2.61 Insider Trans-0.07% Shs Float42.91M Perf Month21.85%
Income-349.10M PEG- EPS next Q-1.48 Inst Own92.00% Short Float17.88% Perf Quarter52.21%
Sales0.08M P/S39207.91 EPS this Y7.40% Inst Trans-3.22% Short Ratio3.32 Perf Half Y83.32%
Book/sh-0.09 P/B- EPS next Y54.00% ROA-74.50% Target Price67.27 Perf Year269.52%
Cash/sh6.12 P/C11.49 EPS next 5Y29.50% ROE-350.10% 52W Range11.57 - 74.94 Perf YTD58.31%
Dividend- P/FCF- EPS past 5Y-29.60% ROI- 52W High-6.16% Beta1.72
Dividend %- Quick Ratio4.30 Sales past 5Y- Gross Margin- 52W Low507.78% ATR3.82
Employees278 Current Ratio4.30 Sales Q/Q- Oper. Margin- RSI (14)60.66 Volatility6.53% 5.80%
OptionableYes Debt/Eq- EPS Q/Q41.30% Profit Margin- Rel Volume0.57 Prev Close68.53
ShortableYes LT Debt/Eq- EarningsFeb 22 AMC Payout- Avg Volume2.31M Price70.32
Recom2.40 SMA2010.44% SMA5013.74% SMA20095.44% Volume1,326,181 Change2.61%
Feb-03-17Downgrade Chardan Capital Markets Neutral → Sell $36
Jan-27-17Initiated BofA/Merrill Buy $74
Jan-26-17Upgrade Piper Jaffray Neutral → Overweight
Jan-23-17Reiterated Stifel Buy $52 → $86
Jan-13-17Initiated Morgan Stanley Overweight
Dec-21-16Reiterated WallachBeth Hold $22 → $49
Dec-20-16Upgrade Chardan Capital Markets Sell → Neutral $15 → $36
Oct-25-16Initiated Chardan Capital Markets Sell $15
Sep-23-16Reiterated SunTrust Buy $38 → $50
Sep-21-16Upgrade Credit Suisse Neutral → Outperform
Sep-21-16Reiterated Stifel Buy $30 → $45
Aug-24-16Reiterated Mizuho Neutral $15 → $23
Aug-05-16Initiated SunTrust Buy
May-09-16Reiterated WallachBeth Hold $30 → $22
Apr-13-16Reiterated Mizuho Neutral $21 → $15
Apr-13-16Downgrade JP Morgan Overweight → Neutral
Apr-13-16Downgrade Credit Suisse Outperform → Neutral
Apr-04-16Resumed Piper Jaffray Neutral
Feb-29-16Reiterated Mizuho Neutral $23 → $21
Feb-26-16Reiterated Stifel Buy $45 → $30
Mar-24-17 06:35PM  SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of the Board of Directors of Clovis Oncology, Inc. - CLVS Accesswire
Mar-22-17 08:02AM  3 Stocks at 52-Week Highs Still Worth Buying at Motley Fool
Mar-21-17 03:02PM  Billionaires' Best Healthcare Stock Picks of 2017 (So Far) at Motley Fool -7.78%
Mar-20-17 03:37PM  Look for Clovis Oncology to Resume Its Advance
Mar-17-17 09:33AM  5 Biotech Companies To Watch In 2017
07:30AM  5 Biotech Companies Set for Major Breakouts In 2017
Mar-16-17 02:49PM  AstraZeneca PLC (ADR) (AZN)s Lynparza Trial Results Positive In Competitive Threat To Clovis Oncology Inc (CLVS) And TESARO Inc (TSRO) at Insider Monkey
08:52AM  3 tech and biotech stocks with momentum at MarketWatch
Mar-15-17 04:15PM  Tesaro Sell-Off On AstraZeneca Ovarian Cancer Trial Overdone: Analyst +7.44%
01:54PM  Heres What Just Happened With AstraZeneca PLC (ADR) (AZN), TESARO Inc (TSRO) And Clovis Oncology Inc (CLVS) at Insider Monkey
01:19PM  AstraZeneca Ovarian Cancer Drug Succeeds in Trial at Investopedia
08:32AM  Lynparza Vs. Niraparib
08:08AM  Clovis Shares Reiterated As A Sell Following 10% Rally
07:46AM  Goldman Sachs Raises Clovis Oncology Price Target to $75
07:30AM  6 Stocks Trending Up With Major Volume
Mar-14-17 04:17PM  Tesaro Trips On AstraZeneca's Ovarian Cancer Trial While Clovis Climbs +10.48%
04:09PM  Why Tesaro is Tanking at Barrons.com
03:43PM  AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results
02:30PM  AstraZeneca ovarian cancer drug slows disease markedly in study
Mar-12-17 10:30AM  Clovis Oncology Presents New Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer at 2017 SGO Annual Meeting on Womens Cancer Business Wire
Mar-01-17 04:22PM  Tesaro Eyes Immuno-Oncology As AstraZeneca, Clovis Loom: Analyst
01:04PM  CLOVIS ONCOLOGY, INC. Financials
Feb-24-17 10:20AM  Merrill Lynch Raises Price Targets on 3 Red-Hot Tech and Biotech Stocks
Feb-23-17 05:19PM  CLOVIS ONCOLOGY, INC. Files SEC form 10-K, Annual Report -5.69%
10:48AM  Clovis Oncology 4Q Loss Below Street Estimates at Investopedia
09:39AM  [2/23] This Weeks Earnings Revisions Movers
08:59AM  Clovis (CLVS) Q4 Loss Wider than Expected; Focus on Rubraca
Feb-22-17 11:58PM  Edited Transcript of CLVS earnings conference call or presentation 22-Feb-17 9:30pm GMT
05:06PM  Clovis reports 4Q loss
04:30PM  Clovis Oncology Inc Earnings Call scheduled for 4:30 pm ET today
04:14PM  CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
04:05PM  Clovis Oncology Announces 2016 Operating Results Business Wire
Feb-18-17 08:41PM  Johnson & Weaver, LLP Announces Investigations of Clovis Oncology, Inc., USANA Health Sciences, Inc., Anthera Pharmaceuticals, Inc., and PixarBio Corporation PR Newswire
Feb-17-17 04:31PM  AstraZeneca Could Give Pfizer, Tesaro Leg Up In Breast Cancer: Leerink +7.22%
01:38PM  Clovis, Tesaro Soar on Astrazeneca Phase Three News
Feb-14-17 12:40PM  Update in Lawsuit for Investors in shares of Clovis Oncology Inc (NASDAQ:CLVS) announced by Shareholders Foundation GlobeNewswire
Feb-13-17 01:00AM  Morgan Stanley, Twitter, Tesaro: Doug Kass' Views
Feb-09-17 06:05PM  Clovis Oncology to Announce Fourth Quarter/Year-End 2016 Financial Results and Host Webcast Conference Call on February 22 Business Wire
Feb-08-17 04:53PM  3 Scorching Hot Biotech Stocks -- Are They Buys? at Motley Fool +5.68%
12:49PM  Biotech Tesaro Climbs on Takeout Reports
Feb-03-17 06:52AM  Clovis Oncology downgraded by Chardan Capital Markets
Feb-01-17 08:31AM  CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
08:30AM  Clovis Oncology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Rucaparib Prostate Cancer Development Program Business Wire
Jan-31-17 12:59PM  Clovis Oncology Inc (CLVS)s Ovarian Cancer Drug Faces Stiff Competition From AstraZeneca PLC (ADR) (AZN), TESARO Inc (TSRO) at Insider Monkey
Jan-30-17 04:12PM  Tesaro, AstraZeneca Could Shrink Clovis' Ovarian Cancer Drug Pool
07:27AM  3 Mid-Cap Biotech Stocks to Buy in February at Motley Fool
Jan-27-17 08:40AM  Clovis Oncology (CLVS) in Focus: Stock Moves 5.6% Higher
Jan-22-17 01:27PM  3 Biotechs Likely to Be Acquired in 2017 at Motley Fool
Jan-17-17 08:05AM  What's Behind Clovis' (CLVS) One-Year Rally of 146.3%?
Jan-10-17 09:30AM  The Zacks Analyst Blog Highlights: Clovis Oncology, Pfizer, Roche's, Sanofi and Regeneron Pharmaceuticals
Jan-09-17 10:48AM  CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stateme +10.49%
08:00AM  Clovis Oncology to Present at the 35th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-04-17 09:40PM  Clovis Oncology Announces Exercise in Full of Underwriters Option to Purchase Additional Shares of Common Stock Business Wire
09:43AM  Clovis Declares Pricing of Upsized Offering of Common Stock
Jan-03-17 06:45PM  Clovis Oncology Announces Upsizing and Pricing of Public Offering of Common Stock Business Wire
11:10AM  Tuesdays Biggest Biotech and Pharma Moves
06:45AM  Clovis Oncology Announces Proposed Offering of Common Stock Business Wire
06:35AM  17 Thoughts on Biotech Stocks to Kick Off 2017
Dec-30-16 04:22PM  Biotech Stocks: What to Watch in 2017 at Motley Fool
Dec-28-16 08:35AM  Eight Milestones Of 2016 In The War On Cancer at Forbes
Dec-27-16 02:32PM  Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week
Dec-23-16 01:32PM  Growth-stock speculators need to tap the brakes here at MarketWatch
Dec-22-16 09:36AM  2016's Worst Clinical Failures at Motley Fool
07:21AM  Christmas Came Early for These Biotech Stocks at Motley Fool
Dec-21-16 03:26PM  4 stocks to watch at MarketWatch +8.65%
02:22PM  4 Stocks With Technical Momentum
Dec-20-16 04:25PM  Tesaro Ovarian Cancer Drug Gets Priority Review After FDA OKs Clovis Med +5.04%
07:17AM  Clovis Scales 52-Week High on Early FDA Nod for Rubraca
Dec-19-16 08:41PM  Surprise! Clovis Oncology Nabs Early OK at Motley Fool +8.82%
05:09PM  Stock Market Roundup, Dec. 19: GOOGL & BBRY Self-Driving Cars, CLVS Soars
05:04PM  US FDA clears ovarian cancer drug for hard-to-treat disease
04:26PM  Clovis Stock Rallies After AstraZeneca-Rivaling Ovarian Cancer Win
04:16PM  Supernus Pharmaceuticals Breaks Out On Up Day For Biotech Stocks
03:53PM  Clovis Wins Key FDA Approval on Ovarian Cancer Treatment
02:52PM  ADDING MULTIMEDIA and CONFERENCE CALL DETAILS Clovis Oncology Announces FDA Accelerated Approval of RUBRACA (rucaparib) for the Monotherapy Treatment of Advanced Ovarian Cancer in Women with Deleterious Germline or Somatic BRCA Mutations.. Business Wire
01:50PM  Here's Why Clovis Oncology (CLVS) Stock Is Soaring Today
01:48PM  Stocks Higher As 3 Medicals Hit Buy Points; No 'Star Wars' Hasbro Bump
01:45PM  Clovis's ovarian cancer drug wins accelerated FDA approval Reuters
12:21PM  Clovis Oncology Gets FDA Approval for New Ovarian Cancer Drug at TheStreet
12:19PM  Clovis Oncology spikes 15% after cancer drug receives early FDA approval at CNBC
11:56AM  Clovis Oncology's ovarian cancer treatment gets FDA OK at MarketWatch
11:27AM  FDA grants accelerated approval to Clovis's ovarian cancer drug
11:16AM  Clovis Oncology Secures FDA Approval for New Ovarian Cancer Drug
Dec-13-16 12:22PM  Short-Sellers Are Betting Big Against Clovis Oncology -- Here's Why They're Probably Right at Motley Fool
Dec-09-16 03:20PM  Are Successful Investors Right To Be So Bearish on Synergy Resources Corp (SYRG)? at Insider Monkey
Dec-07-16 04:32PM  Ariad Pharma Could Draw M&A Fire Ahead Of Second Cancer Drug Win
Dec-05-16 05:54AM  Here is What Hedge Funds Think About Gener8 Maritime Inc (GNRT) at Insider Monkey
Dec-04-16 01:04PM  7 of the Most Shocking Biotech Pipeline Blowups of 2016 at Motley Fool
Dec-01-16 11:44AM  Lifshitz & Miller Law Firm Announces Investigation of Adeptus Health Inc., Avid Technology, Inc., Cempra, Inc., Clovis Oncology, Inc., Impax Laboratories, Inc., Ligand Pharmaceuticals Incorporated, Pattern Energy Group Inc. and Kandi Techno PR Newswire
Nov-30-16 02:25PM  Newman Ferrara LLP Announces Corporate Governance Investigation of Clovis Oncology Inc. Business Wire
12:54PM  Does Clovis Oncology Inc (CLVS) Represent a Good Addition to Your Portfolio? at Insider Monkey
Nov-28-16 02:12PM  Clovis Oncology, Inc. :CLVS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 -8.00%
Nov-23-16 03:44PM  Vetr Crowd Doesn't Like Outlook For Clovis Oncology +5.78%
Nov-17-16 07:51PM  Robbins Arroyo LLP: Clovis Oncology, Inc. (CLVS) Misled Shareholders According to a Recently Filed Lawsuit Business Wire
Nov-10-16 06:36AM  Here's Why These Biopharma Stocks Soared at Least 10% Today at Motley Fool
Nov-09-16 02:36PM  Westmoreland Coal Company (WLB), Corrections Corp Of America (CXW): Heres Why Traders Are Piling Into These Stocks at Insider Monkey +17.69%
Nov-07-16 07:31AM  Clovis (CLVS) Stock Up on Narrower-than-Expected Q3 Loss
Nov-05-16 10:07AM  Clovis 3Q Loss $66 Million or $1.70 a Share (CLVS) at Investopedia
Nov-04-16 12:49PM  CLOVIS ONCOLOGY, INC. Files SEC form 10-Q, Quarterly Report
05:42AM  Edited Transcript of CLVS earnings conference call or presentation 3-Nov-16 8:30pm GMT
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. The company is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications. It distributes its product primarily through specialty distributors and pharmacy providers to patients and health care providers. The company has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and Celgene Corporation; and collaboration and license agreement with Les Laboratoires Servier. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
IVERS-READ GILLIAN CSee RemarksMar 15Sale66.993,000200,970209,583Mar 15 05:15 PM